Navigation Links
AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
Date:4/29/2009

QUEBEC CITY, April 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced it has received notification from the Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Listing Rule 5450 (a) (1) relating to the maintenance of a minimum bid price.

Pursuant to this rule, the Company was required to evidence a closing bid price of at least $1.00 per share for a period of ten consecutive trading days. AEterna Zentaris completed this period on April 27, 2009.

AEterna Zentaris has confirmed that it currently meets all requirements for continued listing on the Nasdaq Global Market and continues to be listed on this exchange.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
2. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
3. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
4. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
5. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
8. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
9. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Sterlitech is proud to announce that it is ... of products . These additional products increase the ... filters with surface charges. , “We have ... membrane process testing equipment, and correspondingly, a wider demand ... Sterlitech President Mark Spatz. “The addition of Synder ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
... Reported in CUSTOM I, II, and III ... ... ,XTENT, Inc. (Nasdaq: XTNT ) today announced positive long-term follow-up,data from ... the Custom NX(R) drug eluting stent (DES) system in treating,patients with coronary ...
... Proximity Systems ... WorkStations: one year later, ... 400,Proximity Systems Computer WorkStations, Centerpoint Medical Center offers,favorable reviews ... are satisfying the needs of the,hospital,s nurses, physicians, patients, ...
... Mentice, a leading,supplier of solutions for medical simulation, ... President of Global Marketing., Effective from today ... marketing activities globally from a corporate standpoint., ... of experience of global,sales, marketing and product management ...
Cached Biology Technology:Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years 2Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years 3In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 2In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 3In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 4Mentice Appoints Bjorn Larsson as Vice President of Global Marketing 2
(Date:9/1/2014)... microscopy revealed the presence of tiny blob-like structures that ... still don,t know what they do even though ... be crucial to the life of a cell, and ... In the Journal of Cell Biology , two ... backgrounds, from biophysics to cell biology, to focus their ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... malaria diagnosis has changed very little. After taking a blood ... a glass slide, stains it with a special dye, and ... the disease. This approach gives an accurate count of how ... of disease severity but is not ideal because there ... the Singapore-MIT Alliance for Research and Technology (SMART) has now ...
Breaking Biology News(10 mins):Scientists call for investigation of mysterious cloud-like collections in cells 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3
... incurable disorder that results from the death of certain neurons ... behavior and movements. The neurodegenerative disease is caused by ... abnormal expansion in a part of DNA, called a CAG ... A healthy version of the Htt gene has between 20 ...
... NY, December 11, 2013 Mary Ann Liebert, Inc., publishers ... and Repositioning , a dynamic new peer-reviewed journal that ... for approved drugsparticularly for disorders where no animal model, ... identified. The Journal will be published online with open ...
... December 2013 Six life science researchers will receive ... the scientists to relocate and set up their research ... EMBO Installation Grants are awarded annually to strengthen science ... talented young group leaders in coming back to their ...
Cached Biology News:Staying ahead of Huntington's disease 2Drug Repurposing, Rescue, and Repositioning: A groundbreaking new journal from Mary Ann Liebert, Inc. 26 Installation Grants awarded 2
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Request Info...
MOUSE ANTI HUMAN FACTOR I...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: